Business Context and Reporting Period
Alterity Therapeutics Limited, a development stage enterprise, filed this Form 6-K for the month of August 2026. The registrant is headquartered in Melbourne, Australia, and files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate actions rather than financial performance data.
Material Changes
The primary material event disclosed is the submission of an application for the quotation of securities (ATH) on the Australian Securities Exchange, included as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. The document serves primarily to incorporate the securities quotation application by reference into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the status and approval of the securities quotation application (Exhibit 99.1) with the relevant exchange.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for details on the securities being quoted.
- Confirm the company's continued status as a development stage enterprise and its cash runway in subsequent filings.